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BRIEF REPoRT
Introduction: We conducted a phase II trial of dasatinib in malig-
nant mesothelioma (MM) patients to evaluate its toxicity and efficacy 
as a second-line treatment.
Methods: Patients with unresectable MM and no symptomatic 
effusions were given dasatinib 70 mg twice daily as part of a 28-day 
cycle. We also measured plasma vascular endothelial growth factor 
and platelet-derived growth factor  and colony stimulating factor 
1 (CSF-1) and mesothelin-related protein at baseline and during 
therapy.
Results: Forty-six patients were enrolled in this study. Fifty 
percent of the first 12 patients enrolled experienced grade 
3 treatment-related adverse events, and therefore, the starting 
dose was reduced to 50 mg twice daily. Grade 3 and 4 toxicities 
included fatigue (11%) and pleural effusion (9%). The overall dis-
ease control rate was 32.6%, and progression-free survival at 24 
weeks was 23% (95% confidence interval: 13.5–40.0%). Survival 
was markedly longer in patients with lower pretreatment CSF-1 
levels and in patients whose CSF-1 levels decreased from baseline 
during therapy.
Discussion: Single-agent dasatinib has no activity in MM and is 
associated with pulmonary toxicities that prohibit its use in an unse-
lected MM population.
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Cisplatin in combination with pemetrexed is now a standard first-line treatment for malignant mesothelioma (MM).1 
However, once patients fail treatment with a pemetrexed-
containing regimen, there is no standard of care available. 
Dasatinib, an aminothiazole analog, is an orally administered 
protein tyrosine kinase inhibitor with activity against several 
dysfunctional signaling pathways in MM, including the SRC 
family kinases, vascular endothelial growth factor (VEGF), 
platelet-derived growth factor  (PDGF) receptor, and sev-
eral other protein tyrosine kinases.2,3 This study was based on 
the hypothesis that dasatinib would have direct and indirect 
antiproliferative effects on mesothelioma and would slow dis-
ease progression no longer controlled with first-line platinum 
and pemetrexed therapy. As secondary endpoints, we analyzed 
the effect of dasatinib on plasma VEGF and PDGF levels. In 
addition, we followed levels of serum CSF-1 because it acti-
vates mitogen-activated protein kinase in myeloid progenitors 
through an SRC-dependent mechanism4 and serum meso-
thelin-related protein because it is known to be decreased in 
patients responding to mesothelioma therapy.5
PATIENTS AND METHODS
Patient Selection
Eligible patients were .18 years of age, had histo-
logically confirmed MM not amenable to curative surgery, 
had unidimensionally measurable disease, and an Eastern 
Cooperative oncology Group performance status of 0 to 1. 
Patients were excluded if they were pregnant, nursing, on anti-
thrombotic or antiplatelet agents, or had documented brain 
metastases, symptomatic pleural effusion, or serious cardiac 
disease, or bleeding disorders. Patients were required to fail 
one and only one pemetrexed-containing chemotherapy regi-
men. Patients were allowed to have received prior intrapleural 
therapy with sclerosing agents or bleomycin. At least 4 weeks 
were required since prior major surgery and 4 weeks since 
first-line chemotherapy or radiotherapy to lesions other than 
those used for measurement. Patients were required to have 
adequate hematologic, hepatic, and renal function and an elec-
trocardiogram showing a QTc interval of ,450 milliseconds. 
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All patients provided informed consent before receiving study 
treatment, and the study was approved by the Institutional 
Review Boards of participating institutions.
Treatment Schedule
Dasatinib was given orally at an initial fixed dose of 
70 mg twice daily. After 23 patients had enrolled, however, 
the dose was reduced to 50 mg twice daily because of poor 
tolerance, including fatigue and pleural effusion. one cycle 
was defined as 28 days.
Study Endpoints and Analysis
The primary objective of this study was to determine 
the rate of progression-free survival (PFS) at 24 weeks. 
Secondary objectives included description of (1) response 
rate (complete response [CR] 1 partial response [PR]); (2) 
response duration; (3) overall survival (oS); (4) toxicity; and 
(5) analysis of plasma VEGF and PDGF and serum CSF-1 
and mesothelin-related protein levels. Response assessment 
was performed using modified RECIST criteria as described 
before.6 A computed tomography scan was performed at 
baseline and every 8 weeks until the patient had documented 
progression. Plasma VEGF was analyzed using Human 
VEGF Quantikine ELISA kit (R&D Systems, Minneapolis, 
MN), and plasma PDGF was analyzed using Human 
PDGF-AB ELISA kit (Insight Genomics, Falls Church, VA). 
Serum CSF-1 levels were detected using Human M-CSF 
Immunoassay Quantikine kit (R&D Systems, Minneapolis, 
MN), and serum mesothelin-1-related protein levels were 
analyzed using MESoMARK assay (Fujirebio Diagnostics, 
Inc, Malvern, PA).
Sample Size Considerations
Sample size was determined as before7 by applying the 
following considerations: if the true 24-week PFS rate for the 
single agent was 54%, we would conclude that the agent was 
worthy of further investigation. However, if the true 24-week 
PFS rate was 34%, we would conclude that the agent was 
not worthy of further investigation. Under constant hazards, 
a 24-week PFS of 34 and 54% corresponded to a median 
PFS of 3.55 months and 6.22 months or a hazard ratio (HR) 
of 1.75. Forty-three eligible patients were to be enrolled in 
the study. The probability of erroneously concluding that the 
treatment was worthy of further investigation (p  0.54) when 
the success rate was truly 34% (p  0.34) was 0.06. The 
probability of erroneously concluding that the treatment was 
not worthy of further investigation (p  0.34) when the suc-
cess rate was truly 54% (p  0.54) was 0.13. If 19 or fewer 
(42.9%) eligible patients were successful in their treatment, 
we would conclude that the treatment was not worthy of addi-
tional investigation.
Statistical Analysis
oS was measured from the day of registration until 
date of death; living patients were censored at the date of 
last follow-up. PFS was measured from the day of regis-
tration until disease progression or death, whichever came 
first; living patients who did not progress were censored at the 
date of last follow-up. Progression was defined as at least a 
20% increase in the sum of the longest diameter of target 
lesions or the appearance of one or more new lesions. Kaplan-
Meier estimates were used to illustrate PFS and oS curves. 
The correlation of response rate and biomarkers was exam-
ined using Wilcoxon rank sum test. In multivariate analysis, 
a logistic regression model was used to explore the relation-
ship of response rate and biomarkers after adjusting for other 
significant prognostic factors. To examine the relationship 
between these biomarkers and PFS and oS, a log-rank test 
and a Cox’s proportional hazard model was used, after adjust-
ing for other prognostic factors.
RESULTS
Drug Safety
Forty-six patients were enrolled in this study from 
September 15, 2007, to August 31, 2009, (Table 1). Three 
patients withdrew from the study before treatment initia-
tion, leaving 43 patients eligible for evaluation. Six of the 
first 12 patients experienced grade 3 adverse events. After 
23 patients had enrolled in the study, the starting dose of dasa-
tinib was decreased from 70 to 50 mg twice daily. The most 
common grade 3 and 4 nonhematologic events were fatigue 
(11%), pleural effusion (9%), and dyspnea (7.5%). one patient 
developed grade 3 pericardial effusion. The most common 
grade 3 or 4 hematologic events (7% of patients) were grade 
3 anemia (2%) and lymphopenia (4%). A greater percentage 
TABLE 1. Baseline Characteristics
Variable n 5 46a
Age  
 Median, yr (range) 68 (35–81)
Gender  
 Male 31 (72%)
 Female 12 (28%)
ECoG performance status  
 0 19 (44%)
 1 24 (56%)
Site of origin  
 Pleura 36 (84.0%)
 Peritoneum 6 (14.0%)
 other 1 (2.0%)
Histology  
 Epithelial 33 (77%)
 Biphasic 5 (12%)
 Sarcomatoid 2 (5%)
 Missing 3 (7%)
Prior therapy  
 Chemotherapy 43 (100%)
 Radiation 6 (14.0%)
 Surgery 23 (53%)
aThree patients were excluded because they withdrew from study before starting 
therapy.
ECoG, Eastern Cooperative oncology Group; N, number of patients.
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of grade 3 toxicities was seen in patients receiving 70 mg of 
dasatinib (52%) compared with 50 mg of dasatinib (39%).
Treatment Response
Most patients stopped therapy because of disease 
progression (56%) or adverse events (12%). The median 
follow-up time was 84 weeks as of April 29, 2011. No CRs 
were observed (Table 2). Although PRs were seen in 4.7% of 
patients (95% confidence interval [CI]: 0.6–15.8%) and sta-
ble disease in 28% of patients, progressive disease was seen 
in 42% of patients. The 24-week PFS rate was 23% (95% 
CI: 13.5–40.0%). The 48-week PFS rate was 2.3% (95% 
CI: 0.3–16.1%). The clinical benefit rate (CR 1 PR 1 SD) 
was 32.6% (95% CI: 19.1–48.5%). Median PFS was 9.1 
weeks (95% CI: 7.4–16.9). Median oS was 26.1 weeks (95% 
CI: 18.6–36.7), with a 1-year survival rate of 25.6%. Thirty-
eight deaths had occurred at the time of analysis. No differ-
ence in oS or PFS was observed in log-rank analysis between 
patients treated with the initial or reduced dose of dasatinib 
(p 5 0.68 and p 5 0.82, respectively).
Correlative Data
Biomarker levels were measured before therapy and 
at the end of the first and second cycle of therapy, and HRs 
were then estimated for risk of death (Table 3). A higher 
level of CSF-1 before treatment was associated with shorter 
oS (Figure 1) (HR 5 1.63, 95% CI: 1.01–2.64; p 5 0.046; 
n 5 36). A decrease in CSF-1 levels from baseline to the end 
of cycle 2 was associated with longer PFS (HR 5 6.67, 95% 
CI: 1.13–39.4; p 5 0.037; n 5 11), and the median PFS for 
these patients was 25 weeks.
DISCUSSION
This phase II study of single-agent dasatinib in 
patients with previously treated MM demonstrated that 23% 
of subjects were progression free at 24 weeks. This percent-
age is less than the prespecified 42% needed to declare the 
regimen worthy of further investigation. Additionally, both 
median PFS (9.1 weeks) and median oS (26.1 weeks) are 
comparable to those seen with best supportive care in a 
recent randomized study.8 The only biomarker associations 
observed were that oS was markedly longer in patients 
with lower pretreatment CSF-1 levels and PFS was nearly 
three times longer (25 weeks) in patients whose CSF-1 
levels decreased from baseline during therapy. Both of 
these observations support the notion that CSF-1 may 
play a role in more aggressive mesothelioma biology and 
are consistent with other studies predicting poor survival 
in patients with Hodgkin lymphoma,9 metastatic colorec-
tal carcinoma,10 prostate cancer,11 and non-small cell lung 
cancer.12 SRC participates in regulation of CSF-1 activation 
of mitogen-activated protein kinase in myeloid progeni-
tors,4 and SRC inhibition has been reported to impair down-
stream signaling from the CSF-1 receptor.13 Identification 
of tumors with molecular markers of sensitivity to SRC 
inhibition or dasatinib may be a more successful strategy in 
future clinical studies testing inhibition of this pathway in 
mesothelioma.
Despite promising preclinical data suggesting that 
SRC plays a critical role in advanced MM, our clinical study 
suggests that dasatinib is inactive in unselected patients 
TABLE 2. Best Responses to Treatmenta
Best Response n Percentage
Partial response 2 5
Stable disease 12 28
Progressive disease 18 42
Unevaluableb 6 14
Early deathsc 4 9
Missing 1 2
Total 43 100
aExcludes canceled patients.
bSix “unevaluable” patients had off treatment dates before day 1 of the third cycle, 
when the first on-treatment computed tomography scan was scheduled. Four had patient 
refusal as an off-treatment reason; one withdrew; one because of adverse event, and one 
as “other.”
cFour patients had “early deaths” (i.e., patient did not survive to day 1 of the third 
cycle) when the first on-treatment computed tomography scan was scheduled.
TABLE 3. Hazard Ratios for Risk of Death According to 
Biomarker Levels
Overall Survival Progression-free Survival
p
Hazard Ratio 
(95% CI) p
Hazard Ratio 
(95% CI)
Pre-VEGFa  
(n 5 38)
0.96 1.00 (0.92–1.1) 0.19 1.06 (0.97–1.15)
VEGF: log  
(cycle 1/pre)  
(n 5 20)
0.71 1.08 (0.72–1.62) 0.41 0.83 (0.58–1.30)
VEGF: log  
(cycle 2/pre)  
(n 5 13)
0.95 1.01 (0.69–1.48) 0.84 1.04 (0.74–1.45)
Pre-PDGF  
(n 5 38)
0.92 0.97 (0.93–1.07) 0.61 1.02 (0.95–1.09)
PDGF: log  
(cycle 1/pre)  
(n 5 20)
0.61 0.86 (0.47–1.56) 0.10 0.60 (0.32–1.11)
PDGF: log  
(cycle 2/pre)  
(n 5 13)
0.60 1.14 (0.70–1.85) 0.51 1.15 (0.76–1.74)
Pre- CSF-1b  
(n 5 36)
0.05 1.63 (1.01–2.64) 0.27 1.27 (0.83–1.96)
CSF-1: log  
(cycle 1/pre)  
(n 5 17)
0.15 0.37 (0.10–1.41) 0.27 0.53 (0.17–1.64)
CSF-1: log  
(cycle 2 /pre) 
(n 5 11)
0.11 5.47 (0.67–44.7) 0.04a 6.67 (1.13–39.4)
MRP (n 5 36) 0.52 0.99 (0.96–1.02) 0.53 1.01 (0.98–1.04)
MRP: log (cycle 
1/pre) (n 5 17)
0.23 1.95 (0.66–5.75) 0.14 2.24 (0.77–6.49)
MRP: log (cycle 
2/pre) (n 5 11)
0.63 1.32 (0.42–4.12) 0.11 2.67 (0.80–8.91)
aPretreatment VEGF values in the model were divided by 100 for more interpretable 
hazard ratios.
bM-CSF values in the model were divided by 1000 for more interpretable hazard 
ratios.
CI, confidence interval; VEGF, vascular endothelial growth factor; PDGF, platelet-
derived growth factor; CSF, cerebrospinal fluid; MRP, mesothelin-related protein.
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with previously treated unresectable mesothelioma. We there-
fore conclude that the lack of activity and unfavorable toxic-
ity of dasatinib should preclude its further development in an 
unselected mesothelioma patient population.
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